Thymanax, Valdoxan (agomelatine) is a small molecule pharmaceutical. Agomelatine was first approved as Thymanax on 2009-02-19. It has been approved in Europe to treat major depressive disorder. The pharmaceutical is active against melatonin receptor type 1A and melatonin receptor type 1B. In addition, it is known to target 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C.
|Trade Name||Thymanax, Valdoxan|
|Indication||major depressive disorder|